The encouraging data from our clinical programs validate the support our investors have shown. We are very pleased to fortify our outstanding investor syndicate with new investors of the highest quality.

211

This significant infusion of equity capital will be utilized to advance our proprietary pipeline of novel therapeutics through clinical trials, including both MD-1100 and our Phase I cholesterol absorption inhibitor MD-0727.

105